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PDGF signal transduction inhibition ameliorates experimental merular diseases in humans, a major cause of end-stage
mesangial proliferative glomerulonephritis. renal failure throughout much of the world. The mecha-
Background. Platelet-derived growth factor (PDGF) has nisms underlying these changes are incompletely under-been consistently implicated in the cell proliferation and extra-
stood, although studies conducted over the past 15 yearscellular matrix accumulation, which characterize progressive
suggest a key role for growth factors in the pathogenesisglomerular disease. In the present study, the effects of a potent
and selective inhibitor of PDGF receptor tyrosine kinase, STI of renal injury [1]. While many act in a pleiotropic fash-
571, were examined in vitro and in vivo. ion, increasing evidence suggests that the effects of spe-
Methods. Cultured mesangial cells were incubated with PDGF cific growth factors predominate in certain physiological(50 ng/mL) and fibroblast growth factor-2 (FGF-2; 50 ng/mL)
and pathological situations [2–5].and treated with STI 571 (0.13 to 2.0 mmol/L). Experimental
Platelet-derived growth factor (PDGF) has been widelymesangial proliferative glomerulonephritis was induced in
male Wistar rats with monoclonal OX-7, anti-rat Thy-1.1 anti- implicated in the pathogenesis of progressive renal injury
body with rats randomized to receive either STI 571 (50 mg/kg in both human disease and experimental models [6].
intraperitoneally daily) or vehicle. Animals were examined six PDGF is synthesized by resident renal cells [7, 8] anddays later.
by infiltrating macrophages [8] that are frequently associ-Results. In vitro, both PDGF and FGF-2 induced a threefold
increase in mesangial cell 3H-thymidine incorporation. STI 571 ated with progressive renal injury [9]. The actions of
reduced PDGF but not FGF-2–stimulated mesangial cell prolif- PDGF include stimulation of mesangial cell proliferation
eration in a dose-dependent manner, with complete abolition [10], increased extracellular matrix (ECM) synthesis [11],
at 0.4 mmol/L. In animals with Thy-1.1 glomerulonephritis,
and increased expression of the prosclerotic cytokine,PDGF receptor tyrosine kinase blockade was associated with
transforming growth factor-b (TGF-b) [12]. Further-significant reductions in mesangial cell proliferation (P ,
0.001), the number of activated (a-smooth muscle positive) more, PDGF levels are also increased in response to a
mesangial cells, and glomerular type IV collagen deposition variety of factors that have been implicated in renal
(P , 0.001). disease, including angiotensin II [13], endothelin [14],Conclusion. The amelioration of the pathological findings
inflammatory cytokines [15], and advanced glycation endof experimental mesangial proliferative glomerulonephritis by
blockade of PDGF receptor activity suggests the potential clini- products [11, 12].
cal utility of this approach as a therapeutic strategy in glomeru- Specific inhibition of PDGF action is therefore a major
lar disease. target for therapy in glomerular disease. Recently, selec-
tive, receptor tyrosine kinase (RTK) inhibitors with in vivo
activity have been synthesized. Of this class of 2-phenyl-
Cellular proliferation and extracellular matrix accu-
aminopyridines, signal transduction inhibitor (STI) 571
mulation are characteristic features of progressive glo-
is a potent and selective inhibitor of PDGF RTK and
v-Abl kinase (with which it shares substantial homology)
1 See Editorial by Floege and Ostendorf, p. 1592 [16]. Such agents may therefore provide therapeutic po-
tential in the treatment of disorders characterized byKey words: platelet-derived growth factor, extracellular matrix, cell
proliferation, progressive renal disease, STI 571. overexpression of PDGF or v-Abl such as glomerular
disease and chronic myeloid leukemia (CML).Received for publication August 8, 2000
The present study sought first to examine the effectsand in revised form October 26, 2000
Accepted for publication November 6, 2000 of PDGF-RTK inhibition with STI 571 on mesangial cell
proliferation in vitro, and also to determine the efficacyÓ 2001 by the International Society of Nephrology
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of this approach on the pathological hallmarks of experi- counting was performed with a b counter (Wallace Rack-
mental mesangial proliferative nephritis, mesangial pro- beta, Wallac Oy, Turku, Finland). Replicates of six wells
liferation, and matrix accumulation. were used.
Rat anti–Thy-1 nephritis
METHODS
Male Wistar rats (150 to 170 g) were obtained from
Drug preparation Monash Animal Services (Melbourne, Australia). Anti–
STI 571, the properties of which have been previously Thy-1 nephritis was induced in two groups of eight rats
described in detail elsewhere [16], was obtained from by an intravenous injection of 5 mg/kg OX-7 IgG, as
Novartis Pharmaceuticals (generous gift of Dr. E. Buch- previously described [20]. Starting one day after OX-7
dunger, Novartis, Basel, Switzerland). For in vitro studies, IgG administration, animals received daily intraperito-
STI 571 was diluted to 10 mmol/L in dimethyl sulfoxide neal injections with either STI 571 (50 mg/kg) or vehicle
(DMSO). This stock solution was then diluted in cell cul- control (10% DMSO in saline) until killed on day 6, the
ture medium to a final concentration of 0.013 to 2.0 mmol/L. peak of mesangial proliferation in this model [20]. The
For in vivo studies, fresh solution was prepared daily by dose of 50 mg/kg/day was selected on the basis of previ-
dissolving the compound in DMSO (200 mg/mL) and ous studies on the inhibition of tumor growth [16]. The
diluting this stock solution 1:10 in normal saline. administration of STI 571 was commenced 24 hours after
OX-7 administration as mesangiolysis is complete by thisAntibodies
time [20]. Three hours prior to sacrifice, all rats were
Monoclonal OX-7, anti-rat Thy-1.1 antibody was used given an intraperitoneal injection of 50 mg/kg bromo-
for the induction of mesangial proliferative glomerulone- deoxyuridine (BrdU) in order to label cells in the DNA
phritis [17]; macrophages were detected using ED1, anti- synthetic (S) phase of the cell cycle. A group of eight
rat CD68 [18]. Myofibrobalsts were identified by labeling normal rats was also injected with BrdU three hours
with 1A4, anti-human a-smooth muscle actin (Sigma before sacrifice.
Immunochemicals, St. Louis, MO, USA), and M744, anti-
BrdU (Dako, Glostrup, Denmark) was used to identify Proteinuria and renal function assessment
proliferating cells. A polyclonal goat anti-bovine/anti- Twenty-four hour urine collections and blood samples
human type IV collagen antibody (Southern Biotechnol- were taken on day 23 (prior to experiment) and day
ogy, Birmingham, AL, USA) was also used to examine
6. Urinary protein concentration was measured by the
extracellular matrix.
benzethonium chloride method [21]. Serum and urine
creatinine levels were measured using the Jaffe´ rate reac-Mesangial proliferation
tion [22].A well-characterized cloned mesangial cell line (1097)
isolated from Sprague-Dawley rats [19] was used be- Histology
tween passages 20 and 30. For these experiments, cells
Tissues were fixed in 10% neutral-buffered formalinwere cultured in RPMI 1640 Medium (GIBCO, Grand
and were embedded in paraffin. Kidney sections (4 mm)Island, NY, USA) with heat-inactivated fetal calf serum
were stained with periodic acid-Schiff’s reagent (PAS).(FCS), 100 U/mL penicillin, and 100 mg/mL streptomycin
Quantitation of nuclei was performed by examining 50in humidified 5% CO2 atmosphere at 378C. Mesangial
hilar glomeruli per animal.cells were plated out at low density in 96-well flat-bot-
tomed microtiter plates in RPMI/10% FCS and allowed
Immunohistochemistry
to adhere overnight. The subconfluent cells were then
Type IV collagen. Immunostaining for type IV colla-starved for three days in RPMI/0.5% FCS. A 48-hour
gen was performed as previously described [23]. In brief,proliferation assay was then performed. STI 571 0.013
kidney sections were rehydrated and treated with 1%to 2.0 mmol/L or drug diluent was then added to cells in
H2O2/methanol followed by incubation in Protein Block-RPMI/0.5% FCS followed in 30 minutes by the addition
ing Agent (Lipshaw-Immunon, Pittsburgh, PA, USA) forof either recombinant PDGF-BB 50 ng/mL (Boehringer-
20 minutes at room temperature. Sections were thenMannheim, Mannheim, Germany) or recombinant fi-
incubated with type IV collagen antibody for 60 minutesbroblast growth factor-2 (FGF-2; Calbiochem, La Jolla,
at room temperature, washed in PBS, and incubated withCA, USA) 50 ng/mL. During the last six hours of culture,
biotinylated goat anti-rabbit immunoglobulin (Dako, Car-0.5 mCi/well 3H-thymidine was added. Cells were then
pinteria, CA, USA) followed by incubation with avidin-harvested by removing the medium, washing twice in
biotin peroxidase complex (ABC; Vector, Burlingham,warm phosphate-buffered saline (PBS), and dissolving
CA, USA). Peroxidase conjugates were subsequently lo-in 100 mL 0.2 mol/L sodium hydroxide. This solution was
then neutralized with hydrochloric acid, and scintillation calized using diaminobenzidine tetrahydrochloride (DAB)
Fig. 2 Fig. 4
Gilbert et al: PDGF signal transduction inhibition 1327
b
Fig. 2. Photomicrograph of PAS-stained kidney section from control
animals (A), rats with experimental mesangial proliferative glomerulo-
nephritis receiving either vehicle (B) or STI 571 (C). Magnification
3360. Compared with control animals, untreated rats show marked
glomerular hypercellularity and mesangial matrix expansion. STI 571–
treated rats show near normal glomerular histology. Reproduction of
this figure in color was made possible by a grant from Novartis, Aus-
tralia.
b
Fig. 4. Effects of STI 571 on mesangial cell proliferation as assessed
by double immunostaining with BrdU (blue color) and ED1 (brown
color). Photomicrograph showing macrophages (ED 11, brown), prolif-
erating macrophages (BrdU1/ED 11 cells, blue and brown) and prolif-
erating mesangial cells (BrdU1/ED 12 cells, blue) in control animals Fig. 1. Effects of STI 571 on platelet-derived growth factor (PDGF)-
(A) and rats with experimental mesangial proliferative glomerulone- stimulated DNA synthesis. Data are expressed as mean 6 SD. *P ,
phritis receiving either vehicle (B) or STI 571 (C) treatment was associ- 0.001 vs. PDGF (50 ng/mL) without STI 571. †P , 0.001 vs. medium.
ated with reduced mesangial cell proliferation. Magnification 3360.
Reproduction of this figure in color was made possible by a grant from
Novartis, Australia.
as a chromogen. Sections were then counterstained with
Mayer’s hematoxylin.
a-Smooth muscle actin. Immunostaining for a-smooth
muscle actin was performed in formalin fixed tissue sec-
tions using a microwave-based technique to prevent anti-
body cross-reactivity, as previously described [24]. In
brief, sections were microwave treated for 10 minutes in
0.01 mol/L sodium citrate buffer, pH 6.0, and then la-
beled with a-smooth muscle actin antibody using a three-
layer peroxidase-antiperoxidase method and developed
with 3,3-DAB (Sigma) to produce a brown color.
ED 1 and BrdU: Double staining. Double immunohis-
tochemical staining was performed in formalin-fixed tis-
sue sections using a microwave-based technique to pre-
vent antibody cross-reactivity, as previously described
[24]. In brief, sections were labeled with ED 1 as de- Fig. 3. Glomerular cellularity as assessed by the number of nuclei
(mean 6 SD) per glomerular cross-section (gcs) in 50 hilar glomeruliscribed above for a-smooth muscle actin. Sections were
per animal. Glomerular hypercellularity was significantly attenuated by
then microwave treated for a second time, labeled at STI 571. *P , 0.05 vs. control; †P , 0.05 vs. untreated.
48C with M744 anti-BrdU antibody using the three-layer
phosphatase-antiphosphatase method, and developed
with fast blue BB salt (Ajax Chemicals, Melbourne, Aus-
were scored under high power (3400), and the differenttralia) to produce a blue color. Sections had a weak
populations were expressed as the mean 6 SD per glo-counterstain with PAS and mounted in aqueous medium.
merular cross-section. As podocytes do not proliferateNegative controls. Sections incubated with protein
and glomerular endothelial cells account for ,3% ofblocking agent instead of primary antisera served as neg-
proliferating cells in this OX-7–induced disease modelative controls. Tissues were also incubated with irrele-
[24], proliferating cells were identified as either macro-vant isotype control antibodies as previously described
phages (ED 11BrdU1) or mesangial cells (ED 12[24]. Tissues treated in this manner showed no positive
BrdU1) as previously described [24]. All scoring wasstaining.
performed with the observer masked to the study group.
Quantitation of immunohistochemistry The magnitude of immunostaining for a-smooth mus-
cle actin or type IV collagen was quantitated using com-Sections double stained with BrdU and ED 1 antibody
puter-assisted image analysis as previously describedwere used to quantitate for ED 11BrdU1, ED 11
BrdU2, and ED 12BrdU1 cells. Fifty hilar glomeruli [25, 26]. In brief, for each tissue section, images from
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three nonoverlapping, randomly selected fields were ex-
amined by light microscopy (Olympus BX-50; Olympus
Optical, Tokyo, Japan) and digitized using a high-resolu-
tion camera (Fujix HC-2000; Fujifilm, Tokyo, Japan).
All images were obtained using a 320 objective lens.
Digitized images were then captured on a Power Macin-
tosh G3 computer (Apple Computer Inc., Cupertino,
CA, USA) equipped with an in-built graphic board and
opened using analytical software (Analytical Imaging
Software, Ontario, Canada).
The area of brown on an immunoperoxidase-stained
section was selected for its color range, and the propor-
tional area of tissue with this range of color was then
quantitated on 50 hilar glomeruli per animal such that
the magnitude of immunolabeling was expressed as the
proportional area of the tissue section that stained brown.
Statistics
Fig. 5. Mesangial cell proliferation as assessed by the number of
All data are shown as mean 6 SE unless otherwise BrdU1/ED 12 cells (mean 6 SEM) per glomerular cross-section (gcs)
in 50 hilar glomeruli per animal. Mesangial cell proliferation was signifi-specified. Data were analyzed by analysis of variance
cantly attenuated by STI 571. *P , 0.001 vs. control; †P , 0.001 vs.(ANOVA) using the StatView IV program (Brainpower,
untreated.
Calabasas, CA, USA) on a Macintosh G3. Comparisons
between group means were performed by Fisher’s least
significant difference method. A P value of less than 0.05
was considered statistically significant. Glomerular cellularity and mesangial cell proliferation
in rats with anti–Thy-1 nephritis
Animals with anti–Thy-1 nephritis displayed moderateRESULTS
glomerular hypercellularity when compared with control
PDGF-induced mesangial cell proliferation in vitro
animals, as assessed by the nuclear counting; however,
The ability of PDGF to stimulate proliferation in se- glomerular hypercellularity was significantly reduced in
rum-starved mesangial cells was inhibited by pretreat- rats treated with STI 571 (Fig. 3). Mesangial cell
ment of cells with STI 571 in a dose-dependent fashion (BrdU1ED 12) proliferation was increased 16-fold com-
(Fig. 1). Complete inhibition of PDGF-induced mesan- pared with control rats and significantly reduced by treat-
gial 3H-thymidine incorporation was seen at 2 mmol/L. ment with STI 571 (Figs. 4 and 5). Similarly, the propor-
In contrast, mesangial proliferation induced by FGF-2 tional area of glomeruli immunostained for a-smooth
was unaffected by STI 571 (data not shown). Mesangial muscle actin indicating activated mesangial cells was also
cells remained viable, as evidenced by trypan blue exclu- increased in untreated rats with anti–Thy-1 nephritis and
sion and the maintenance of normal mesangial cell ap- significantly reduced by the administration of STI 571
pearance and, in particular, nuclear morphology. (Figs. 6 and 7). In contrast, STI 571 had no effect on
either glomerular macrophage numbers (Fig. 8A) or
Clinical characteristics their proliferative activity (Fig. 8B).
The administration of OX-7 IgG both with and with-
Glomerular matrix accumulationout STI 571 was well tolerated by all experimental ani-
mals with no weight loss or abnormalities in hemoglobin, Marked accumulation of immunostainable type IV
leukocyte, or platelet counts. Proteinuria was mildly collagen was present in untreated rats with anti–Thy-1
increased in animals that received OX-7 IgG compared nephritis and was significantly reduced by the adminis-
with control rats and was unaffected by STI 571 treat- tration of STI 571 (Figs. 6 and 7).
ment (normal control, 2.1 6 0.2 mg/24 hours; vehicle-
treated Thy-1 nephritis, 13.4 6 7.2 mg/24 hours; STI 571-
DISCUSSIONtreated Thy-1 nephritis, 16.4 6 7.0 mg/24 hours). In
PAS-stained sections, mesangial hypercellularity and in- In the present study, blockade of PDGF receptor activ-
creased mesangial matrix were noted in glomeruli of ity in experimental mesangial proliferative glomerulone-
untreated rats. These pathological changes were not seen phritis was associated with a reduction in the pathological
hallmarks of this disease: hypercellularity and extracellu-in rats receiving STI 571 (Fig. 2).
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Fig. 6. Immunostaining for a-smooth muscle actin (left panel) and type IV collagen (right panel) in photomicrograph of kidney section from
untreated (A), and STI 571-treated rats (B) with experimental mesangial proliferative glomerulonephritis. Magnification 3360.
lar matrix accumulation. Additionally, the antiprolifera- sion may be particularly relevant to more chronic glo-
merular diseases in which mesangial matrix correlatestive effects of PDGF receptor blockade on mesangial
cells were confirmed in vitro. These findings attest to the closely with declining glomerular filtration rate [27–29].
In the present study, the reduction in extracellular matrixcentral role of PDGF in glomerular disease and provide
a new therapeutic strategy for its treatment. resulting from STI 571 administration may reflect changes
in both direct and indirect PDGF related processes. ForThe major findings of the present study were the ame-
lioration of mesangial hypercellularity and matrix accu- instance, while PDGF may directly stimulate extracellu-
lar matrix synthesis [30], it is also possible that the ob-mulation by treatment with STI 571. Not only was
PDGF-induced mesangial proliferation abrogated in vitro, served changes may have been a consequence of the
fewer activated, synthetic-type, a-smooth muscle actin-but also in vivo, as shown by a reduction in cell nuclei
and BrdU1ED 12 cells. In addition to these effects on positive mesangial cells [31]. In addition, the ability of
PDGF to stimulate expression of the prosclerotic cyto-cell proliferation, mesangial matrix expansion was also
reduced by PDGF-RTK inhibition as evidenced in both kine TGF-b in mesangial cells [12] suggests that such
interactions may also contribute to the reduction in ex-PAS-stained sections and in tissues immunostained for
the major glomerular extracellular matrix protein, type tracellular matrix observed in the present study.
The cellular actions of PDGF follow the binding ofIV collagen. Such effects on extracellular matrix expan-
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Fig. 7. Activated mesangial cells (A) and type IV collagen deposition
(B) as assessed by the proportional area immunostained with a-smooth
muscle actin and type IV collagen antibodies, respectively. Data are
expressed as (mean 6 SEM) per glomerular cross-section (gcs) in 50
hilar glomeruli per animal from untreated and STI 571–treated rats.
*P , 0.05.
ligand to the extracellular part of its receptor. This in
turn leads to its dimerization and autophosphorylation
Fig. 8. Quantitation of macrophage numbers (ED 11, A) and macro-ultimately leading to protein kinase C activation and con-
phage proliferation (B), as assessed by the number of ED 11/BrdU1sequent cell responses [6, 32]. STI 571 is a potent and cells (mean 6 SEM) per glomerular cross-section (gcs) in 50 hilar
selective inhibitor of the PDGF receptor (PDGF-R) and glomeruli per animal. *P , 0.01 vs. control.
Abl protein tyrosine kinases [33]. While STI 571 is a
potential treatment for Bcr-Abl–positive leukemias, its
inhibitory effects on PDGFR activation suggests a poten-
no effect on FGF-2–induced mesangial 3H-thymidine in-tial role in nonmalignant diseases in which PDGF has
corporation. By selectively targeting PDGF signaling,been strongly implicated, such as glomerulonephritis. In
STI 571 administration in the in vivo setting resulted incontrast to its effects on the PDGF receptor, ligand-
cell-specific inhibition of mesangial cell, but not macro-induced autophosphorylation of the receptors for epider-
phage proliferation within the glomerulus.mal growth factor, insulin-like growth factor I, and FGF
Numerous studies have reported PDGF overexpres-are insensitive to STI 571, with IC50 .200-fold greater
sion in a variety of human [34–38] and experimentalthan for PDGF RTK [33]. Indeed, in the present study,
glomerular diseases [39–41]. However, while there is sub-STI 571 specifically inhibited PDGF-induced mesangial
cell proliferation in a dose-dependent manner, but had stantial evidence suggesting that this overexpression of
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PDGF is of major pathogenetic significance in glomeru- a direct role in the pathogenesis of this form of experi-
mental glomerulopathy, although it may provide a sourcelar disease [6], in order to establish a role for a specific
cytokine in renal disease, it has been proposed that four of excessive PDGF in this disease.
In summary, the strong association of both experimen-criteria need to be satisfied [2]. These criteria, an adapta-
tion of Koch’s postulates, state the following: (1) the tal and human mesangial proliferative glomerulonephri-
tis with PDGF overexpression and the amelioration ofcytokine must have the relevant biological effect on tar-
get cells in vitro; (2) it should be expressed in disease the pathological findings in the present study by blockad-
ing PDGF receptor activity suggest the potential clinicalstates and correlate with the proposed biological effect;
(3) its administration in vivo should reproduce the dis- utility of this approach as a therapeutic strategy in glo-
merular disease.ease; and (4) blocking the cytokine should ameliorate
the disease. While there is substantial experimental data
to satisfy the first three criteria for PDGF’s role in glo- ACKNOWLEDGMENTS
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